SurModics IVD, Inc., a wholly owned subsidiary of SurModics, Inc.
(NASDAQ:SRDX) and a market leader for in
vitro diagnostic assay components, today announced the launch of BioFX®
Liquid Nova-Stop Solution, a non-corrosive, non-hazardous stop
solution for TMB microwell substrates.
“We know assay developers are always seeking the safest possible
products that still deliver top performance,” says Joe Stich, vice
president and general manager of SurModics’ IVD business. “BioFX Liquid
Nova-Stop Solution represents a major improvement over traditional stop
solutions that contain sulfuric acid or hydrochloric acid. It also
delivers key performance in terms of minimal signal drift.”
ELISA assay kit manufacturers can include BioFX Liquid Nova-Stop
Solution in their products without needing to label and ship the
products as “corrosive.” This means added convenience for kit
manufacturers and their customers, as well as reduced transportation
costs by avoiding surcharges related to shipping corrosive or hazardous
materials. This is particularly relevant as companies seek to comply
with requirements of the United Nation’s Globally Harmonized System of
Classification and Labeling of Chemicals (GHS).
In the U.S., GHS implementation occurs through the Occupational Health
and Safety Administration’s revised Hazard Communication Standard (HCS).
As of June 1, 2015, OSHA will require hazardous chemical labels to
include pictograms and hazard and precautionary statements, among other
items. Many standard TMB stop solutions containing hydrochloric or
sulfuric acids will need to comply with GHS/OSHA labeling requirements.
Because the new BioFX Liquid Nova-Stop Solution is non-corrosive and
non-hazardous, no GHS labeling is required.
SurModics IVD offers a full range of innovative solutions, including
custom formulations, for the in vitro diagnostics industry. To
learn more, visit our website (www.surmodics.com/ivd),
or contact customer service (952-500-7200 or orders@surmodics.com).
More than 900 IVD products are available for online ordering at shop.surmodics.com.
About SurModics, Inc.
SurModics' mission is to exceed our
customers' expectations and enhance the wellbeing of patients by
providing the world's foremost, innovative surface modification
technologies and in vitro diagnostic chemical components. The
Company partners with the world's leading and emerging medical device,
diagnostic and life science companies to develop and commercialize
innovative products designed to improve patient diagnosis and treatment.
Core offerings include (i) surface modification coating technologies
that impart lubricity, prohealing, and biocompatibility capabilities,
and (ii) components for in vitro diagnostic tests and
microarrays. SurModics is headquartered in Eden Prairie, Minnesota. For
more information about the Company, visit http://www.surmodics.com.
The content of SurModics' website is not part of this release or part of
any filings the Company makes with the SEC.
SurModics and BioFX are registered trademarks of SurModics, Inc.
and/or its affiliates.
Copyright Business Wire 2014